Melbourne Australia:  Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2012.

The cash balance at 31 December 2012 was $33.2 million.  The cash balance excludes the Company’s anticipated R&D tax incentive refund of $5.3 million receivable this financial year.

Total operating and investing cash outflows for the quarter were $4.4 million.  The cash burn for the quarter is in line with expectations, with the outflows largely relating to the two bacterial vaginosis (BV) clinical programs for VivaGel^®  (treatment and prevention of recurrence).  A significant proportion (>50%) of the Company’s YTD cash flow is attributable to the non-recurrent costs for these two clinical programs and this expenditure is eligible for a 45% rebate under the R&D Tax Incentive program.  Results of Starpharma’s Phase 2 clinical trial of VivaGel^® for the prevention of recurrence of BV are expected in Q1 2013.

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 109kb)